| Objectives By using zoledronic acid for the treatment of secondary osteoporosis (OP) in patients with rheumatoid arthritis (RA), to observe and analyze the clinic indexes of paitents after the treatment, and to evaluate the clinical efficacy and safety of zoledronic acid. Methods All the patients were given an intravenous infusion of 5mg zoledronic acid. The follow-ups were performed at the 6th month and the 12th month after the treatment. DXA, ESR, serum RF, and CRP was detected. The probability of the hip fractures in the next 10 years was calculated using FRAX. Result BMD of L 3, zone Ward, trochanter, femoral neck at 12 months compared with those before treatment is significant. The rest had no significant difference, but there is an increasing trend. In without oral hormone group with RA, hip fracture probability of 12 months compared with those before treatment is significant. For OP patients with RA zoledronic acid treatment would decrease disease activity score28, ESR and CRP ,and it is significant compared with before treatment. Conclusion Zoledronic acid can significantly improve the bone quality, improve bone mineral density, and reduce the probability of fractures in RA paitents with secondary OP in a short term. It also has certain inhibiting effect on the activity of rheumatoid. |